Growing Clinical Capabilities FHI Clinical's recent acquisition of TCD Global and expansion into full-service CRO capabilities, especially for COVID-19 related immunotherapy trials, present opportunities to support scaling clinical research services for pharmaceutical companies seeking expert partnerships in complex trial management.

Diverse Global Reach With operations in nearly 75 countries and a team of approximately 450 staff, FHI Clinical offers extensive geographic and therapeutic coverage, making it an attractive partner for global pharma firms aiming to decentralize or expand their clinical trials into emerging markets.

Focus on Infectious Diseases FHI Clinical's active involvement in COVID-19 projects and malaria vaccine development suggests a strong expertise in infectious disease research, presenting sales opportunities with companies developing vaccines and therapies in this high-growth area.

Innovation and Technology Use Utilizing advanced tech tools such as Microsoft Power Automate and Deltek Time & Expense, FHI Clinical demonstrates a commitment to operational efficiency and data-driven approaches, appealing to clients looking for technologically adept CRO partners to streamline trials.

Mid-Market Positioning With revenue estimates between $50M and $100M and a focused employee base, FHI Clinical is positioned as a flexible mid-sized CRO offering personalized service and competitive pricing, providing potential entry points for small to medium-sized pharmaceutical and biotech companies seeking reliable research partners.